Moving from late to early stage disease: lessons learned from erlotinib in pancreatic can

At the time the CONKO-005 trial was originally conceived, there was an inherent rationale to its design; it represented the next logical step in trying to move the needle in the treatment of early-stage pancreatic adenocarcinoma.